PSTV News & Events

Plus Therapeutics provided a business update. Notably, the company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to (CNSY), effective August 3. Furthermore, the company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit.

Plus Therapeutics files $100M mixed securities shelf

Plus Therapeutics announced that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver an AI execution platform for CNS oncology. The AI execution platform is designed to integrate, organize, and derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus' CNS oncology technology programs.